贝伐珠单抗联合表皮生长因子受体络氨酸激酶抑制剂治疗非小细胞肺癌的研究进展  

Research progress of Bevacizumab combined with epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer

作　　者：张新毅[1] 张美云[1] ZHANG Xin-yi;ZHANG Mei-yun(Department of Oncology,Baotou Cancer Hospital,Inner Mongolia Autonomous Region,Baotou014030,China)

机构地区：[1]内蒙古自治区包头市肿瘤医院肿瘤科,内蒙古包头014030

出　　处：《中国当代医药》2020年第11期27-30,共4页China Modern Medicine

基　　金：内蒙古自治区卫生计生科技计划项目(201701103)。

摘　　要：肺癌是目前世界上发病率和死亡率最高的恶性肿瘤,其中大多数病理类型是非小细胞肺癌(NSCLC)。表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)类药物的出现,显著延长了NSCLC患者的生存时间,然而多数患者用药后会产生耐药。贝伐珠单抗通过抑制人类血管内皮生长因子活性,抑制血管形成,具有较好的抗肿瘤的作用。贝伐珠单抗与EGFR-TKI类药物作用于不同的肿瘤生长途径,两类药物有潜在的互补机制来控制肿瘤生长,联合应用治疗NSCLC具有充足的理论依据和应用前景。本文现就贝伐珠单抗与EGFR-TKI治疗NSCLC的研究进展进行综述。Lung cancer is the most common malignancy with the highest morbidity and mortality worldwide, most of which are non-small cell lung cancer(NSCLC). Epidermal growth factor receptor tyrosine kinase inhibitors(EGFRTKI) drugs significantly prolonged the survival time of NSCLC patients, but most patients developed drug resistance.Bevacizumab inhibited the activity of human vascular endothelial growth factor and inhibited the formation of blood vessels effectivly, which has better antitumor effect. Bevacizumab and EGFR-TKI drugs act on different tumor growth pathways, and these two drugs have potentially complementary mechanisms to control tumor. The combined treatment of NSCLC has sufficient theoretical basis and application prospect. This article reviews the research progress of Bevacizumab and EGFR-TKI in the treatment of NSCLC.

关 键 词：贝伐珠单抗 表皮生长因子受体酪氨酸激酶抑制剂 非小细胞肺癌 联合治疗 

分 类 号：R734.2[医药卫生—肿瘤]